Login to Your Account



Oxygen Biotherapeutics gains altitude after FDA lifts Oxycyte clinical hold

By Marie Powers
Staff Writer

Tuesday, March 4, 2014
Shares of Oxygen Biotherapeutics Inc. (NASDAQ:OXBT) climbed as much as 35 percent Tuesday after the company reported the FDA lifted the clinical hold on Oxycyte, clearing the path for the company to resume U.S. studies.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription